{"analyses":[{"ciLowerLimit":"0.503","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.985","estimateComment":"The hazard ratio was estimated using the Cox proportional hazards model, stratified by AML status (de novo, secondary) and age (18 - \\< 75, ≥ 75).","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.040","paramType":"Hazard Ratio (HR)","paramValue":"0.704","statisticalComment":"Log-rank test stratified by AML status (de novo, secondary) and age (18 - \\< 75, ≥ 75).","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.514","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.000","estimateComment":"The hazard ratio was estimated using the Cox proportional hazards model.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.049","paramType":"Hazard Ratio (HR)","paramValue":"0.717","statisticalComment":"Unstratified analysis","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.1","upperLimit":"8.1","value":"4.1"},{"groupId":"OG001","lowerLimit":"5.9","upperLimit":"10.1","value":"8.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"143"}],"units":"Participants"}],"description":"Overall survival is defined as the time from the date of randomization to the date of death. Participants who had not died were censored at the date they were last known to be alive on or before the cutoff date. Overall survival was analyzed using Kaplan-Meier methodology.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received matching placebo to venetoclax orally once a day (QD) plus cytarabine 20 mg/m² subcutaneously on Days 1 to 10 of each 28-day cycle.","id":"OG000","title":"Placebo + Low Dose Cytarabine (LDAC)"},{"description":"Participants received venetoclax 600 mg orally once a day plus cytarabine 20 mg/m² subcutaneously on Days 1 to 10 of each 28-day cycle.","id":"OG001","title":"Venetoclax + Low Dose Cytarabine (LDAC)"}],"paramType":"MEDIAN","populationDescription":"Full analysis set","reportingStatus":"POSTED","timeFrame":"From randomization until the 6-month follow-up analysis cut-off date of August 15, 2019; the median follow-up time was 17.7 months (range: 0.2-20.8) in the placebo arm and 17.5 months (range: 0.1-23.5) in the venetoclax arm.","title":"Overall Survival After an Additional 6-Months Follow-up","type":"POST_HOC","unitOfMeasure":"months"}